HTG Molecular Diagnostics Valuation
| HTGMDelisted Stock | USD 0.57 0.20 54.05% |
HTG Molecular is overvalued. HTG Molecular Diagnostics retains a regular Real Value of $0.54 per share. The prevalent price of the firm is $0.57. Our model calculates the value of HTG Molecular Diagnostics from analyzing the firm fundamentals such as Current Valuation of 2.56 M, return on asset of -0.62, and Return On Equity of -3.43 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that HTG Molecular's price fluctuation is very steady at this time. Calculation of the real value of HTG Molecular Diagnostics is based on 3 months time horizon. Increasing HTG Molecular's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the HTG stock is determined by what a typical buyer is willing to pay for full or partial control of HTG Molecular Diagnostics. Since HTG Molecular is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HTG Stock. However, HTG Molecular's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.57 | Real 0.54 | Hype 0.57 |
The intrinsic value of HTG Molecular's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence HTG Molecular's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of HTG Molecular Diagnostics helps investors to forecast how HTG stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HTG Molecular more accurately as focusing exclusively on HTG Molecular's fundamentals will not take into account other important factors: HTG Molecular Total Value Analysis
HTG Molecular Diagnostics is currently forecasted to have valuation of 2.56 M with market capitalization of 1.06 M, debt of 4.83 M, and cash on hands of 14.1 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the HTG Molecular fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.56 M | 1.06 M | 4.83 M | 14.1 M |
HTG Molecular Investor Information
The company recorded a loss per share of 17.1. HTG Molecular Diagnostics last dividend was issued on the 23rd of November 2020. The entity had 1:12 split on the 21st of December 2022. Based on the analysis of HTG Molecular's profitability, liquidity, and operating efficiency, HTG Molecular Diagnostics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.HTG Molecular Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. HTG Molecular has an asset utilization ratio of 35.81 percent. This suggests that the Company is making $0.36 for each dollar of assets. An increasing asset utilization means that HTG Molecular Diagnostics is more efficient with each dollar of assets it utilizes for everyday operations.HTG Molecular Ownership Allocation
HTG Molecular retains 6.54 (percent) of its outstanding shares held by insiders and 0.74 (percent) owned by outside corporations.HTG Molecular Profitability Analysis
The company reported the previous year's revenue of 6.37 M. Net Loss for the year was (21.59 M) with loss before overhead, payroll, taxes, and interest of (2.01 M).About HTG Molecular Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of HTG Molecular Diagnostics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of HTG Molecular Diagnostics based exclusively on its fundamental and basic technical indicators. By analyzing HTG Molecular's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of HTG Molecular's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of HTG Molecular. We calculate exposure to HTG Molecular's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of HTG Molecular's related companies.HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. Htg Molecular operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.
HTG Molecular Growth Indicators
Investing in growth stocks can be very risky. If the company such as HTG Molecular does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 889.3 K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in HTG Stock
If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |